NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
Novo Nordisk »05/03/2007 [Company watch]
Novo Nordisk and Chinese Academy of Science establish Research Foundation

Novo Nordisk have committed $2million to co-fund research activities of mutual interest - diabetes and biopharmaceuticals.




 Novo Nordisk and the Chinese Academy of Science (CAS) have signed an agreement that establishes a joint research foundation in China. The aim of Novo Nordisk–Chinese Academy of Science Research Foundation is to fund or co-fund activities of common interest within the fields of diabetes and biopharmaceuticals, including related disciplines and technologies such as protein chemistry, immunology, inflammation, toxicology, oncology, endocrinology and drug delivery.

"We look forward to a fruitful cooperation with Novo Nordisk," says Professor Chen Zhu, CAS vice president and chair person of the Foundation. "Chinese and Danish scientists share a history of excellent collaborations which the new foundation will further strengthen. Novo Nordisk is well recognised in China for its major role in preventing and treating diabetes. We are very pleased to collaborate with Novo Nordisk and believe the collaboration will be of great benefit to both parties."

In January 2002, Novo Nordisk established a world class R&D centre in Beijing, which is the first R&D centre in China established by international bio-pharmaceutical companies. After five years of R&D activity in China, Novo Nordisk decided to cooperate with CAS and fund 2,000,000 US dollars in supporting research in diabetes and biopharmaceuticals.

"This cooperation illustrates the great attention Novo Nordisk pays to China as well as our long-term commitment to help in further developing the Chinese healthcare system," says Dr Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. He also emphasises that Novo Nordisk will continue to launch new products in China and increase the company’s R&D presence in the country


5 Mar 2007 :

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.